Related Experiment Video
Updated: Mar 12, 2026
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy
Chiara Ambrogio1, Ernest Nadal2, Alberto Villanueva3
1Experimental Oncology, Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.
Abstract:
Understanding the early evolution of cancer heterogeneity during the initial steps of tumorigenesis can uncover vulnerabilities of cancer cells that may be masked at later stages. We describe a comprehensive approach employing gene expression analysis in early lesions to identify novel therapeutic targets and the use of mouse models to test synthetic lethal drug combinations to treat human Kirsten rat sarcoma viral oncogene homologue (KRAS)-driven lung adenocarcinoma.
Insights
Early cancer evolution reveals vulnerabilities for targeted therapies. Researchers identified new therapeutic targets in early lung adenocarcinoma lesions using gene expression analysis and mouse models.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Cancer heterogeneity evolves early in tumorigenesis, potentially masking critical vulnerabilities.
- Understanding these early changes is crucial for developing effective cancer treatments.
Approach:
- Gene expression analysis was performed on early-stage lesions of Kirsten rat sarcoma viral oncogene homologue (KRAS)-driven lung adenocarcinoma.
- Mouse models were utilized to investigate synthetic lethal drug combinations as a therapeutic strategy.
Key Points:
- Early tumorigenesis presents unique cancer cell vulnerabilities.
- Novel therapeutic targets can be identified through gene expression analysis of early lesions.
- Synthetic lethal drug combinations show promise for treating KRAS-driven lung adenocarcinoma.
Conclusions:
- Targeting early-stage cancer evolution offers a promising therapeutic avenue.
- This research provides a foundation for developing novel treatments for KRAS-driven lung adenocarcinoma.
- Further investigation into synthetic lethality could lead to breakthrough cancer therapies.
More Related Videos
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
